Because BET inhibitors inhibit the expression of tumor promoting genes and HDAC inhibitors induce the expression of tumor silencing genes, we explored the synergistic anticancer effects of BET inhibitors (JQ1, OTX015) and an FDA approved pan-HDAC inhibitor panobinostat on the cell growth of MYC-amplified and non-MYC-amplified MB cell lines using a standard MTT assay. The gene discussed is HDAC9; the disease is neoplasm.